Accelerating antibody therapy with INTEGRA pipettes

INTEGRA Biosciences has awarded 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips worth US $1000 and various lab accessories to UK-based start-up Creasallis, helping to accelerate its pioneering research into improving the penetration of therapeutic antibodies into tumors.

The prize – part of the recent ‘INTEGRA supports start-ups’ competition – will allow the company to accurately pipette volumes of 0.2 to 5000 μl, increasing the laboratory’s capabilities as it continues to grow and innovate in this novel area of antibody research.

Creasallis was founded in 2021 to overcome one of the major limitations of antibody therapies: their inability to effectively penetrate tumors, resulting in only surface-level treatment. The young company has already made significant scientific advancements in this area with its groundbreaking, patented CreaTap (Creasallis Tumor Antibody Penetration) plug-and-play technology, which can be incorporated into any existing antibody.

Creasallis currently operates in a multi-use laboratory at the Babraham Research Campus, and previously only had access to a limited number of communal pipettes, shared between different companies, regardless of their primary research focus. The trailblazing team was therefore thrilled to win the ‘INTEGRA supports start-ups competition’, which ran until April 2023. Dr Joyce Ratti, Head of Protein Sciences at Creasallis, explained: “It is a very generous prize, far greater than I expected.

Our 50 brand new EVOLVE manual pipettes will allow us to designate a set to each task – such as cell culture or protein work – helping to prevent contamination. Having access to different volumes ranges is also hugely beneficial, making pipetting different quantities much easier and far more accurate. Most importantly, we now have the resources to expand our capabilities in the lab and take on more employees in the future when we are ready, accelerating this novel area of research.”

Read more about Creasallis and how it will use INTEGRA’s liquid handling solutions.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    INTEGRA Biosciences. (2024, February 13). Accelerating antibody therapy with INTEGRA pipettes. News-Medical. Retrieved on May 28, 2024 from https://www.news-medical.net/news/20231129/Accelerating-antibody-therapy-with-INTEGRA-pipettes.aspx.

  • MLA

    INTEGRA Biosciences. "Accelerating antibody therapy with INTEGRA pipettes". News-Medical. 28 May 2024. <https://www.news-medical.net/news/20231129/Accelerating-antibody-therapy-with-INTEGRA-pipettes.aspx>.

  • Chicago

    INTEGRA Biosciences. "Accelerating antibody therapy with INTEGRA pipettes". News-Medical. https://www.news-medical.net/news/20231129/Accelerating-antibody-therapy-with-INTEGRA-pipettes.aspx. (accessed May 28, 2024).

  • Harvard

    INTEGRA Biosciences. 2024. Accelerating antibody therapy with INTEGRA pipettes. News-Medical, viewed 28 May 2024, https://www.news-medical.net/news/20231129/Accelerating-antibody-therapy-with-INTEGRA-pipettes.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
INTEGRA supports the next generation of synthetic biologists